A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2018 According to an Oncolytics Biotech media release, results will be discussed in a conference call for Analysts and Institutional Investors on Wednesday, February 7, 2018 at 8:30 a.m. ET.
    • 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top